Mab-22 (denosumab biosimilar) / Xentria, Nanjing King-Friend Bio, Meitheal Pharmaceuticals - LARVOL DELTA

Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® (clinicaltrials.gov) - P1 | N=225 | Completed | Sponsor: Xentria, Inc. | Recruiting ➔ Completed

Trial completion